Developer docs
API playgroundTry for free, no card

Search company profiles

Blacksmith Medicines

Full company profile

uuid0002vye

Namestring
Blacksmith Medicines
Legal namestring
Blacksmith Medicines
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Blacksmith Medicines is a clinical-stage biopharmaceutical company that develops first-in-class small molecule inhibitors of metal-dependent enzymes (metalloenzymes). The company is headquartered in San Diego, California, with 11-50 employees, and was formed in January 2023 through the merger of Blacksmith Medicines and Forge Therapeutics. It targets metalloenzyme classes historically considered undruggable due to the poor drug-like properties of earlier chemotypes (hydroxamic acid, hydroxyurea). Its internal pipeline comprises three programs: an LpxC antibiotic program (lead candidate FG-2101 with FDA Qualified Infectious Disease Product and Fast Track Designation, plus FG-960 in earlier development) targeting multidrug-resistant Gram-negative bacterial infections; an FEN1 oncology program (BSM-1516) exploiting synthetic lethality in Homologous Recombination-deficient tumors; and a QPCTL cancer immunotherapy program modulating CD47.

The company's core technology is the BLACKSMITH Platform, a purpose-built drug discovery engine that combines a focused fragment library of proprietary metal-binding pharmacophores (MBPs), a comprehensive metalloenzyme genome database, a first-of-its-kind metallo-CRISPR target validation library, and bio-inorganic-informed computational modeling/docking. Patents on proprietary non-hydroxamate LpxC scaffolds and non-hydroxyurea FEN1 scaffolds have been granted in the United States and allowed in Europe, with corresponding filings in China and Japan. Co-founder Seth Cohen, a UCSD professor and metalloenzyme chemist, anchors the science; co-founder David Puerta leads discovery as COO/VP; CEO Zachary Zimmerman leads business operations.

Blacksmith is pre-revenue and monetizes through a mix of non-dilutive government grants (NIAID, CARB-X), enterprise pharma partnership payments and milestone-eligible collaborations (Roche up to $190.5M, Basilea multi-target agreement, Evotec strategic alliance, Zoetis, Active Motif), and expected future product revenue from approved therapeutics. Go-to-market is enterprise field sales executed through pharma co-development partnerships and government contracts rather than direct physician sales, consistent with a clinical-stage licensing-and-platform model.

Short descriptiontext

Blacksmith Medicines is a clinical-stage biopharmaceutical company developing first-in-class small molecule inhibitors of metalloenzymes for serious Gram-negative bacterial infections, DNA-damage-repair-dependent cancers, and CD47-targeted cancer immunotherapy, leveraging its proprietary BLACKSMITH chemistry platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metalloenzyme drug discovery, small molecule inhibitors, antibiotic development, fragment-based drug discovery, anticancer therapeutics
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
Product category
Small Molecule Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Non-dilutive Government Funding
TypeLicensing Royalties
Description

Grants and contracts from government agencies (NIAID, CARB-X) to support clinical development of antibiotic candidates

prnewswire.com
2Pharmaceutical Partnership Payments
TypeLicensing Royalties
Description

Potential milestone payments and royalties from pharmaceutical partnerships (Roche collaboration valued up to $190.5M total)

blacksmithmedicines.com
3Future Product Revenue
TypeOne Time License
Description

Revenue from approved antibiotic and oncology products, once clinical development is completed and regulatory approvals obtained

prnewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Blacksmith Medicines is a clinical-stage biopharmaceutical company that discovers and develops small molecule inhibitors of metal-dependent enzymes (metalloenzymes) for the treatment of serious infectious diseases and cancer. Its lead programs target LpxC for multidrug-resistant Gram-negative bacterial infections and FEN1 for oncology, built on a proprietary BLACKSMITH chemistry platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Effective killing of multidrug-resistant Gram-negative bacteria including ESBL and CRE strains where other antibiotics are ineffective
+2 more records
Product overview1 text field

Blacksmith Medicines is a biopharma company that has developed a purpose-built platform focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes (metalloenzymes). The company's BLACKSMITH Platform comprises a focused fragment library of proprietary metal-binding pharmacophores (MBPs), comprehensive metalloenzyme genome database, first-of-its-kind metallo-CRISPR library, and computational modelling capabilities. The company leverages these technologies across three main programs: the LpxC antibiotic program (lead product FG-2101, with FG-960 in development), the FEN1 oncology program (BSM-1516), and the QPCTL cancer immunotherapy program. The company merged with Forge Therapeutics in 2023 and maintains strategic partnerships with Evotec AG, Roche, Basilea, and Zoetis, with funding support from NIAID and CARB-X.

Product and service2 records
1BLACKSMITH Platform
CategoryDrug Discovery Platform
Description

Purpose-built drug discovery platform focused on small molecule inhibitors of metalloenzymes, integrating proprietary metal-binding pharmacophores, comprehensive metalloenzyme database, metallo-CRISPR library, and computational modeling for fragment-based drug discovery and structure-based drug design.

2FG-2101
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-25
Description

Collaboration to develop novel antibiotic to treat lung infections. Forge eligible to receive up to $190.5M in total payments including upfront, development, regulatory, and sales milestones plus royalties.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-04-24
Description

Multi-target agreement to discover and develop novel antibiotics targeting difficult-to-drug bacterial pathogens.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-12-09
Description

Strategic 'Superbug' Alliance combining innovative chemistry efforts with cutting edge anti-infective drug discovery platform. Expanded in 2017 to launch BLACKSMITH Platform for discovering novel metalloenzyme inhibitors across broad therapeutic areas.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2016-03-28
Description

Collaboration on epigenetic research and drug discovery targeting Jumonji KDMs.

5UCSD (University of California, San Diego)
Strategic tierCoreTypeTechnology or Integration
Description

In-licensed technology from UCSD. Co-founder Seth Cohen is Professor and former Chair of Chemistry and Biochemistry at UCSD. Technology licensed includes metalloenzyme expertise and intellectual property.

blacksmithmedicines.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaborator presenting preclinical data on FG-2101 at IMARI conference. Partnership for academic research and data generation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Animal health company partner listed on company website as partner.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Early-stage biopharmaceutical company focused on developing small molecule inhibitors targeting RNA-modifying enzymes and metalloenzymes for cancer treatment. Emerging player with thematic overlap on metalloenzyme drug discovery platforms targeting oncology.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for MDR bacterial infections, including Gram-negative pathogens. Direct peer in the antibacterial development space.

TypeDirect peer
Description

Clinical-stage biotechnology company developing novel anti-infectives, including antivirals and antibacterial conjugates. Comparable in clinical-stage anti-infective development with novel mechanism focus.

TypeDirect peer
Description

Commercial-stage biopharmaceutical company developing and commercializing antibiotics including Nuzyra for serious community-acquired infections. Comparable antibiotic pipeline focus.

TypeBroad incumbent
Description

Global pharmaceutical major with significant antibacterial franchise and active programs in MDR infections, plus oncology platform. As a broader incumbent, Pfizer represents both potential acquirer and competitive benchmark for Blacksmith's commercial outlook.

TypeDirect peer
Description

Clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, including oral and IV antibiotics for Gram-negative infections. Comparable target indication and regulatory strategy.

TypeDirect peer
Description

Clinical-stage company developing differentiated antibiotics for multidrug-resistant Gram-negative infections (acquired by Innoviva). Direct peer with focus on serious bacterial infections and similar regulatory pathway via QIDP designations.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing antibiotics targeting Gram-negative bacterial infections, including LpxC inhibitors and beta-lactamase inhibitors. Direct competitor to Blacksmith in the antibacterial space with similar mechanism focus.

TypeDirect peer
Description

Commercial-stage company developing and commercializing antibiotics for acute care settings, including treatments for Gram-negative infections. Comparable focus on serious bacterial infections though broader portfolio.

TypeBroad incumbent
Description

Clinical-stage biopharmaceutical company developing antibiotics (ridinilazole for C. difficile) and oncology therapeutics. Broader infectious disease and oncology portfolio provides comparison for Blacksmith's dual-indication strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blacksmith Medicines

Small Molecule Therapeuticsblacksmithmedicines.com

Blacksmith Medicines is a clinical-stage biopharmaceutical company developing first-in-class small molecule inhibitors of metalloenzymes for serious Gram-negative bacterial infections, DNA-damage-repair-dependent cancers, and CD47-targeted cancer immunotherapy, leveraging its proprietary BLACKSMITH chemistry platform.

What Blacksmith Medicines does

Blacksmith Medicines is a clinical-stage biopharmaceutical company that develops first-in-class small molecule inhibitors of metal-dependent enzymes (metalloenzymes). The company is headquartered in San Diego, California, with 11-50 employees, and was formed in January 2023 through the merger of Blacksmith Medicines and Forge Therapeutics. It targets metalloenzyme classes historically considered undruggable due to the poor drug-like properties of earlier chemotypes (hydroxamic acid, hydroxyurea). Its internal pipeline comprises three programs: an LpxC antibiotic program (lead candidate FG-2101 with FDA Qualified Infectious Disease Product and Fast Track Designation, plus FG-960 in earlier development) targeting multidrug-resistant Gram-negative bacterial infections; an FEN1 oncology program (BSM-1516) exploiting synthetic lethality in Homologous Recombination-deficient tumors; and a QPCTL cancer immunotherapy program modulating CD47.

The company's core technology is the BLACKSMITH Platform, a purpose-built drug discovery engine that combines a focused fragment library of proprietary metal-binding pharmacophores (MBPs), a comprehensive metalloenzyme genome database, a first-of-its-kind metallo-CRISPR target validation library, and bio-inorganic-informed computational modeling/docking. Patents on proprietary non-hydroxamate LpxC scaffolds and non-hydroxyurea FEN1 scaffolds have been granted in the United States and allowed in Europe, with corresponding filings in China and Japan. Co-founder Seth Cohen, a UCSD professor and metalloenzyme chemist, anchors the science; co-founder David Puerta leads discovery as COO/VP; CEO Zachary Zimmerman leads business operations.

Blacksmith is pre-revenue and monetizes through a mix of non-dilutive government grants (NIAID, CARB-X), enterprise pharma partnership payments and milestone-eligible collaborations (Roche up to $190.5M, Basilea multi-target agreement, Evotec strategic alliance, Zoetis, Active Motif), and expected future product revenue from approved therapeutics. Go-to-market is enterprise field sales executed through pharma co-development partnerships and government contracts rather than direct physician sales, consistent with a clinical-stage licensing-and-platform model.

Blacksmith Medicines firmographics

Firmographics
Name
Blacksmith Medicines
Legal name
Blacksmith Medicines
Website
https://blacksmithmedicines.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Blacksmith Medicines is a clinical-stage biopharmaceutical company developing first-in-class small molecule inhibitors of metalloenzymes for serious Gram-negative bacterial infections, DNA-damage-repair-dependent cancers, and CD47-targeted cancer immunotherapy, leveraging its proprietary BLACKSMITH chemistry platform.
Ownership category
akta.pro rank

Blacksmith Medicines industry classification

Industry
Product category
Small Molecule Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Metalloenzyme drug discovery
  • Small molecule inhibitors
  • Antibiotic development
  • Fragment-based drug discovery
  • Anticancer therapeutics

Where Blacksmith Medicines is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Blacksmith Medicines business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Others

Revenue model

  1. Non-dilutive Government Funding: Grants and contracts from government agencies (NIAID, CARB-X) to support clinical development of antibiotic candidates
  2. Pharmaceutical Partnership Payments: Potential milestone payments and royalties from pharmaceutical partnerships (Roche collaboration valued up to $190.5M total)
  3. Future Product Revenue: Revenue from approved antibiotic and oncology products, once clinical development is completed and regulatory approvals obtained

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Blacksmith Medicines product offering

Product offering

Core offering

Blacksmith Medicines is a clinical-stage biopharmaceutical company that discovers and develops small molecule inhibitors of metal-dependent enzymes (metalloenzymes) for the treatment of serious infectious diseases and cancer. Its lead programs target LpxC for multidrug-resistant Gram-negative bacterial infections and FEN1 for oncology, built on a proprietary BLACKSMITH chemistry platform.

Product overview

Blacksmith Medicines is a biopharma company that has developed a purpose-built platform focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes (metalloenzymes). The company's BLACKSMITH Platform comprises a focused fragment library of proprietary metal-binding pharmacophores (MBPs), comprehensive metalloenzyme genome database, first-of-its-kind metallo-CRISPR library, and computational modelling capabilities. The company leverages these technologies across three main programs: the LpxC antibiotic program (lead product FG-2101, with FG-960 in development), the FEN1 oncology program (BSM-1516), and the QPCTL cancer immunotherapy program. The company merged with Forge Therapeutics in 2023 and maintains strategic partnerships with Evotec AG, Roche, Basilea, and Zoetis, with funding support from NIAID and CARB-X.

Differentiator

Problem solved

Functional benefit

Products and services

  • BLACKSMITH Platform Purpose-built drug discovery platform focused on small molecule inhibitors of metalloenzymes, integrating proprietary metal-binding pharmacophores, comprehensive metalloenzyme database, metallo-CRISPR library, and computational modeling for fragment-based drug discovery and structure-based drug design.
  • FG-2101

Quantifiable outcome

  • Effective killing of multidrug-resistant Gram-negative bacteria including ESBL and CRE strains where other antibiotics are ineffective
  • +2 more outcomes

Companies that use Blacksmith Medicines

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Blacksmith Medicines technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Blacksmith Medicines partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and minor.

  • RochecoreStrategic or Co-development Partner · 25 March 2020Collaboration to develop novel antibiotic to treat lung infections. Forge eligible to receive up to $190.5M in total payments including upfront, development, regulatory, and sales milestones plus royalties.
  • Basilea PharmaceuticamajorStrategic or Co-development Partner · 24 April 2019Multi-target agreement to discover and develop novel antibiotics targeting difficult-to-drug bacterial pathogens.
  • Evotec AGcoreTechnology or Integration · 9 December 2016Strategic 'Superbug' Alliance combining innovative chemistry efforts with cutting edge anti-infective drug discovery platform. Expanded in 2017 to launch BLACKSMITH Platform for discovering novel metalloenzyme inhibitors across broad therapeutic areas.
  • Active MotifminorStrategic or Co-development Partner · 28 March 2016Collaboration on epigenetic research and drug discovery targeting Jumonji KDMs.
  • UCSD (University of California, San Diego)coreTechnology or IntegrationIn-licensed technology from UCSD. Co-founder Seth Cohen is Professor and former Chair of Chemistry and Biochemistry at UCSD. Technology licensed includes metalloenzyme expertise and intellectual property.
  • University of Wisconsin (David Andes, Ph.D.)minorStrategic or Co-development PartnerAcademic collaborator presenting preclinical data on FG-2101 at IMARI conference. Partnership for academic research and data generation.
  • ZoetisminorStrategic or Co-development PartnerAnimal health company partner listed on company website as partner.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Blacksmith Medicines competitors and assessment

Company assessment

Emerging players

  • 858 Therapeutics: Early-stage biopharmaceutical company focused on developing small molecule inhibitors targeting RNA-modifying enzymes and metalloenzymes for cancer treatment. Emerging player with thematic overlap on metalloenzyme drug discovery platforms targeting oncology.

Direct peers

  • Spero Therapeutics: Clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for MDR bacterial infections, including Gram-negative pathogens. Direct peer in the antibacterial development space.
  • Cidara Therapeutics: Clinical-stage biotechnology company developing novel anti-infectives, including antivirals and antibacterial conjugates. Comparable in clinical-stage anti-infective development with novel mechanism focus.
  • Paratek Pharmaceuticals: Commercial-stage biopharmaceutical company developing and commercializing antibiotics including Nuzyra for serious community-acquired infections. Comparable antibiotic pipeline focus.
  • Iterum Therapeutics: Clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, including oral and IV antibiotics for Gram-negative infections. Comparable target indication and regulatory strategy.
  • Entasis Therapeutics: Clinical-stage company developing differentiated antibiotics for multidrug-resistant Gram-negative infections (acquired by Innoviva). Direct peer with focus on serious bacterial infections and similar regulatory pathway via QIDP designations.
  • VenatoRx Pharmaceuticals: Clinical-stage biopharmaceutical company developing antibiotics targeting Gram-negative bacterial infections, including LpxC inhibitors and beta-lactamase inhibitors. Direct competitor to Blacksmith in the antibacterial space with similar mechanism focus.
  • Melinta Therapeutics: Commercial-stage company developing and commercializing antibiotics for acute care settings, including treatments for Gram-negative infections. Comparable focus on serious bacterial infections though broader portfolio.

Broad incumbents

  • Pfizer: Global pharmaceutical major with significant antibacterial franchise and active programs in MDR infections, plus oncology platform. As a broader incumbent, Pfizer represents both potential acquirer and competitive benchmark for Blacksmith's commercial outlook.
  • Summit Therapeutics: Clinical-stage biopharmaceutical company developing antibiotics (ridinilazole for C. difficile) and oncology therapeutics. Broader infectious disease and oncology portfolio provides comparison for Blacksmith's dual-indication strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Blacksmith Medicines social profiles

Digital presence

Blacksmith Medicines compliance and trust

Trust signal

Compliance2 records

Blacksmith Medicines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blacksmith Medicines leadership team

Management profile

Number of profiles

Profiles3 records

Blacksmith Medicines funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blacksmith Medicines M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blacksmith Medicines

What does Blacksmith Medicines do?

Blacksmith Medicines is a clinical-stage biopharmaceutical company that discovers and develops small molecule inhibitors of metal-dependent enzymes (metalloenzymes) for the treatment of serious infectious diseases and cancer. Its lead programs target LpxC for multidrug-resistant Gram-negative bacterial infections and FEN1 for oncology, built on a proprietary BLACKSMITH chemistry platform.

Is Blacksmith Medicines a public or private company?

Blacksmith Medicines is a private company. It is classified as venture growth investor backed and is currently operating.

When was Blacksmith Medicines founded?

Blacksmith Medicines was founded in 2016. It employs 1 to 10 people.

Where is Blacksmith Medicines based?

Blacksmith Medicines is headquartered in San Diego, United States, in the North America region.

How does Blacksmith Medicines make money?

Three revenue lines are on record. Non-dilutive Government Funding is the primary driver. The others are pharmaceutical Partnership Payments and future Product Revenue.

Who are Blacksmith Medicines's main competitors?

858 Therapeutics is listed as an emerging player. Direct peers are Spero Therapeutics, Cidara Therapeutics, Paratek Pharmaceuticals, Iterum Therapeutics, Entasis Therapeutics, VenatoRx Pharmaceuticals and Melinta Therapeutics. Broad incumbents are Pfizer and Summit Therapeutics.

Does Blacksmith Medicines have an API?

No public API is recorded for Blacksmith Medicines.

What industry is Blacksmith Medicines in?

Blacksmith Medicines's product category is Small Molecule Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 32541.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBlacksmith Medicines Announces Publication in Journal of Medicinal Chemistry Highlighting Discovery of a Non-Hydroxamate LpxC InhibitorBlacksmith Medicines announced the publication of research in the Journal of Medicinal Chemistry detailing the discovery of non-hydroxamate LpxC inhibitors for treating multidrug-resistant Gram-negative infections. The study highlights the company's proprietary chemistry platform, which aims to overcome limitations of previous hydroxamic acid-based approaches through differentiated safety profiles and efficacy in animal models.PR NewswireBlacksmith Medicines Announces Presentation at AACR Annual Meeting 2026Blacksmith Medicines announced it will present data on its oncology program targeting flap endonuclease 1 (FEN1) at the American Association for Cancer Research Annual Meeting 2026, scheduled for April 17-22 at the San Diego Convention Center. The poster presentation (Abstract #234) will showcase proteomic profiling data on BSM-1516, a FEN1 inhibitor, revealing chromatin-associated biomarkers for preclinical pharmacodynamic evaluation, during the DNA Damage and Repair 1 session on April 19. The company highlighted that FEN1 is overexpressed in multiple tumor types and has numerous synthetic lethality partners in the Homologous Recombination pathway, making it a target for anticancer therapeutic development.PR NewswireBlacksmith Medicines and Collaborators to Present at the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)Blacksmith Medicines announced it will present data on its lead antibacterial candidate FG-2101 at the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) being held January 28-30, 2026, in Las Vegas, Nevada. The drug, a first-in-class LpxC inhibitor targeting multidrug-resistant Gram-negative pathogens, will be presented in both talk and poster formats, including data from academic collaborator David Andes, Ph.D. at the University of Wisconsin. The FG-2101 program is supported by a contract with NIAID (75N93022C00060).PR NewswireBlacksmith Medicines Secures European Patent Allowance for LpxC-Targeting Antibacterial CompoundsBlacksmith Medicines announced it received a Notice of Intention to Grant from the European Patent Office for a patent covering its antibacterial compound FG-960, which targets LpxC in Gram-negative bacteria. The patent strengthens its portfolio with similar patents in the US, China, and Japan, supporting the development of its novel antibiotic class.SdbnBlacksmith Medicines Secures European Patent Allowance for LpxC-Targeting Antibacterial Compounds – San Diego Biotechnology NetworkBlacksmith Medicines, a San Diego-based biopharma company focused on metalloenzyme-targeting therapeutics, announced that the European Patent Office has issued a Notice of Intention to Grant for its patent applications covering LpxC-targeting antibacterial compounds. The patent allowance provides intellectual property protection for the company's antibiotic development program in European markets. This development strengthens Blacksmith Medicines' IP portfolio as it advances its antibacterial pipeline targeting metalloenzymes.SdbnBlacksmith Medicines Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for FG-2101, a Novel Antibiotic Targeting LpxC – San Diego Biotechnology NetworkBlacksmith Medicines received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for its novel antibiotic candidate FG-2101, which targets the LpxC enzyme. The FDA designations grant FG-2101 an additional five years of market exclusivity along with priority review status. The company, based in San Diego, is focused on developing medicines targeting metalloenzymes.PR NewswireBlacksmith Medicines Co-Founder Presents at the 21st International Conference on Biological Inorganic ChemistryProfessor Seth Cohen, co-founder of Blacksmith Medicines, delivered a keynote presentation at the 21st International Conference on Biological Inorganic Chemistry in Long Beach, California, highlighting the company's metalloenzyme drug discovery platform and its lead antibiotic candidate FG-2101. FG-2101 is a first-in-class non-hydroxamate LpxC inhibitor designed to treat drug-resistant Gram-negative bacterial infections and has completed IND-enabling studies, with human trials planned for later this year. The presentation was supported by NIAID funding and positioned Blacksmith's proprietary chemistry as a solution to previously undruggable metalloenzyme targets.PR NewswireBlacksmith Medicines Announces Presentation at AACR Annual Meeting 2025Blacksmith Medicines announced it will present data on its FEN1 nuclease inhibitor showing synergy with PARP-targeting drugs at the AACR Annual Meeting 2025 in Chicago on April 29. The presentation (Abstract 5720) covers preclinical oncology research from the company's metalloenzyme-targeted drug discovery platform targeting flap endonuclease 1, an enzyme overexpressed in many tumor types with synthetic lethality partners in the Homologous Recombination pathway. The company has also disclosed its portfolio of strategic drug discovery collaborations with Basilea, Cyteir Therapeutics, Eli Lilly, Roche, and Zoetis.